Immune Aging Follows Nonlinear Peaks in Humans and Mice, Revealing Sex-Specific and Cellular Declines

3 min read
Source: ScienceAlert
Immune Aging Follows Nonlinear Peaks in Humans and Mice, Revealing Sex-Specific and Cellular Declines
Photo: ScienceAlert
TL;DR

New research indicates human immune systems age in two distinct bursts rather than a steady decline. A Singapore study identifies sharp peaks around age 40 and after 60, while a Monash University mouse study reveals that aging immune cells can actively suppress other defenses, complicating cancer and infection risks.

Key points

  • A Duke-NUS study of 1,828 humans found immune gene activity changes sharply at ages 40 and 60, with females showing more pronounced peaks than males.
  • The Singapore research highlights a decline in RNA and protein maintenance during these peaks, which may promote misfolded proteins and disease.
  • A Monash University study in mice identified three genetic pathways that disrupt CD8 T cell function, making older individuals more susceptible to cancer and infections.
  • Researchers discovered a previously unknown group of aging T cells that actively suppress other immune responses, rather than just failing to fight threats.
  • The Monash team also linked the protein granzyme K to age-related damage in the heart, liver, and kidneys, suggesting potential therapeutic targets for organ protection.

Background

Recent studies have explored various aspects of biological aging, including a 2026 report on a 'midlife shift' in sperm RNA and findings that forest hiking reduces inflammation in seniors. A 2024 study previously suggested similar abrupt aging lurches at ages 44 and 60, though it faced statistical criticism. The current findings build on this by providing a more detailed map of immune trajectories, moving away from a one-size-fits-all view of aging.

How outlets are covering it

ScienceAlert emphasizes the nonlinear nature of human immune aging, highlighting sex-specific differences where females experience higher peaks and sustained cancer-fighting T cell activation. In contrast, Genetic Engineering and Biotechnology News and Bioengineer.org focus on preclinical mouse data, stressing the discovery of a new regulatory T cell population that actively inhibits immune defenses. Starts at 60 contextualizes these findings for public health, noting that while the mouse studies offer a blueprint for reversing decline, human applications remain distant, and current strategies like high-dose flu vaccines for the elderly are the practical response to known immune weakening.

Why it matters

Understanding that immune decline occurs in specific bursts rather than a steady fade allows for more precise timing of medical interventions. Identifying that some aging cells actively suppress defenses, rather than just failing, opens new avenues for therapies aimed at restoring immune competence and protecting organs from age-related damage.

What to watch

Researchers will investigate whether the chromatin signatures and cellular phenotypes found in mice translate to humans. The Monash team is also testing if blocking granzyme K later in life can protect organs like the heart and kidneys, while the Singapore team aims to determine why autoimmune conditions disproportionately affect women based on their distinct aging timelines.

Share this article

Want the full story? Read the original reporting

Read on ScienceAlert